StockNews.AI
VERO
StockNews.AI
169 days

Venus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

1. Venus Concept (VERO) will release Q4 2024 results on March 31. 2. A conference call will follow for discussion and Q&A. 3. The company offers a wide range of aesthetic technologies. 4. Venus Concept operates in over 60 countries. 5. Backed by notable healthcare equity investors.

3m saved
Insight
Article

FAQ

Why Neutral?

The release of financial results alone does not guarantee a price movement, as we saw in the past where similar announcements led to both positive and negative reactions, depending on financial performance metrics disclosed during the calls and subsequent market sentiment.

How important is it?

The financial results and guidance from the upcoming earnings call can influence VERO's immediate market perception and investor confidence, thereby impacting stock pricing.

Why Short Term?

The upcoming quarterly results and subsequent call will likely affect short-term investor sentiment and stock price, similar to how quarterly earnings releases traditionally impact market reactions.

Related Companies

TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2024 financial results will be released before the market opens on Monday, March 31, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on March 31, 2025 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13751985. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com. For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13751985. The webcast will be archived at ir.venusconcept.com. About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa PRO, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.

Related News